Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial by Wechsler Michael E, Kunselman Susan J, Chinchilli Vernon M, Bleecker Eugene, Boushey Homer A, Calhoun William J, Ameredes Bill T, Castro Mario, Craig Timothy J, Denlinger Loren, Fahy John V, Jarjour Nizar, Kazani Shamsah, Kim Sophia, Kraft Monica, Lazarus Stephen C, Lemanske Robert F, Markezich Amy, Martin Richard J, Permaul Perdita, Peters Stephen P, Ramsdell Joe, Sorkness Christine A, Sutherland E Rand, Szefler Stanley J, Walter Michael J, Wasserman Stephen I, Israel Elliot, National Heart, Lung and Blood Institute's Asthma Clinical Research Network in Lancet (2009). PubMed

Abstract

Some studies suggest that patients with asthma who are homozygous for arginine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less from treatment with longacting beta2 agonists and inhaled corticosteroids than do those homozygous for glycine (B16 Gly/Gly). We investigated whether there is a genotype-specific response to treatment with a longacting beta2 agonist in combination with inhaled corticosteroid.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.